Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M, Wirth M
Klinik für Urologie, Charité - Universitätsmedizin Berlin.
Aktuelle Urol. 2013 Jan;44(1):45-9. doi: 10.1055/s-0032-1323745. Epub 2012 Sep 26.
Targeted therapies such as sunitinib, pazopanib, bevacizumab, sorafenib and everolimus have become established as new therapeutic standards in the treatment of metastatic renal cell carcinoma. New substances are going to complement these treatment options. Therefore, cytokines as long-term standard therapy are being more and more replaced. The achievements raise a lot of questions in clinical daily routine: Which criteria influence the decision for therapy? How can a remission be assessed when antiangiogenetic agents are administered? And last but not least, the optimal sequence remains a controversially discussed topic. Based on the current study situation, an interdisciplinary expert meeting was held to debate these aspects. Results from the 2010 conference provided the basis for the 2011 meeting. The results of the 2011 conference are presented as short theses.
舒尼替尼、帕唑帕尼、贝伐单抗、索拉非尼和依维莫司等靶向治疗已成为转移性肾细胞癌治疗的新治疗标准。新药物将补充这些治疗选择。因此，作为长期标准治疗的细胞因子正越来越多地被取代。这些成果在临床日常工作中引发了诸多问题：哪些标准会影响治疗决策？使用抗血管生成药物时如何评估缓解情况？最后但同样重要的是，最佳治疗顺序仍是一个备受争议的话题。基于当前的研究状况，召开了一次跨学科专家会议来讨论这些方面。2010年会议的结果为2011年会议提供了基础。2011年会议的结果以简短论文的形式呈现。
